Apixaban Efficacy, Safety Evaluated in AF Patient on Multiple Concomitant Medications
Older patients, females, and those with comorbidities were more likely to be on multiple medications.
Older patients, females, and those with comorbidities were more likely to be on multiple medications.
Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.
Patients were randomized to either 6 weeks of placebo first followed by 6 weeks of isosorbide mononitrate or 6 weeks of isosorbide mononitrate followed by 6 weeks of placebo.
Vericiguat an investigational oral sGC (soluble guanylate cyclase) stimulator.
The new findings were based on data from a pooled analysis of two large U.S. commercial health insurance databases.
Idarucizumab (Praxbind) was recently granted accelerated approval as a reversal agent for patients on Pradaxa during emergency situations.
The Food and Drug Administration (FDA) recently approved a new 60mg dosage strength for Brilinta to be used in patients with a history of MI beyond the first year.
New Haven Pharmaceuticals announced new data that demonstrates Durlaza (aspirin) extended-release capsules provide sustained antiplatelet control for a full 24-hour period in high-risk patients.
PARADIGM-HF study, which included 8,442-patients, is the largest clinical trial ever conducted in heart failure.
Jardiance, a sodium-glucose co-transporter 2 inhibitor, is indicated as adjunct to diet and exercise to improve glycemic control in adults with T2D.